<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification and clinical features of dystrophic epidermolysis bullosa&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification and clinical features of dystrophic epidermolysis bullosa<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Classification and clinical features of dystrophic epidermolysis bullosa<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Type, inheritance, gene, product</td> <td class="subtitle1">Cutaneous symptoms</td> <td class="subtitle1">Mucosal involvement</td> <td class="subtitle1">Nails and hair symptoms</td> <td class="subtitle1">Extracutaneous manifestations</td> </tr> <tr class="divider_bottom"> <td> <p><strong>Localized DDEB</strong><br/> (previously encompassing nails only, pretibial, and acral DDEB)</p> <p>AD</p> <p><em>COL7A1</em><br/> (monoallelic missense, splice-site mutations with in-frame exon skipping; deletion mutations within triple helical domain)</p> <p>Type VII collagen</p> </td> <td> <ul> <li>Predominantly acral or pretibial skin fragility, usually from birth or early childhood (acral) or later childhood/adulthood (pretibial) </li> <li>Risk of cutaneous SCC </li> <li>EB nevi may occur </li> </ul> </td> <td> <ul> <li>Oral mucosa </li> </ul> </td> <td> <ul> <li>Nails only variants with progressive dystrophy and loss (toenails) </li> </ul> </td> <td>Â </td> </tr> <tr class="divider_bottom"> <td> <p><strong>Intermediate DDEB</strong><br/> (previously known as generalized DDEB)</p> <p>AD</p> <p><em>COL7A1</em><br/> (monoallelic missense, splice-site, or deletion mutations; somatic mosaicism for a dominant glycine substitution mutation)</p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized skin fragility, scarring, and milia from birth or early childhood, predilection for <strong>bony prominences</strong> (elbows, knees, ankles, and dorsa of the hands and feet) </li> <li>Increased risk of cutaneous SCC </li> <li>EB nevi may occur </li> </ul> </td> <td> <ul> <li>Oral mucosa </li> <li>Oesophageal blistering </li> <li>Recurrent blistering and fissuring around anal margin, exacerbating constipation </li> <li>Involvement of the conjunctiva and cornea (corneal erosions, scarring, pannus, symblepharon formation, reduced visual acuity) </li> <li>Urethral strictures </li> </ul> </td> <td> <ul> <li>Nail dystrophy and loss secondary to trauma </li> </ul> </td> <td> <ul> <li>Nutritional impairment due to reduced intake (microstomia, dental caries, oesophageal stricture disease) in combination with increased metabolic demands because of chronic wounds, infection, inflammation </li> <li>Constipation (anal fissuring and blistering, exacerbated by poor intake of fiber-rich foods) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>Intermediate RDEB</strong><br/> (previously known as RDEB generalized intermediate, non-Hallopeau-Siemens RDEB)</p> <p>AR</p> <p><em>COL7A1</em><br/> (biallelic missense, nonsense, deletion, insertion, small insertion/deletion, or splice-site mutations with compound heterozygosity for a loss-of-function mutation on one <em>COL7A1</em> allele and a non-loss-of-function mutation on the second allele; revertant mosaicism [somatic mutation and intragenic crossover] and forward nonrevertant mosaicism [germline frameshift mutation and somatic splice-site mutation])</p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized skin fragility, scarring, and milia from birth or early childhood, predilection for <strong>bony prominences</strong> </li> <li>Mutilating deformities generally missing, mild flexion contractures of fingers and limited digital fusion in proximal digital web spaces possible </li> <li>Striate pattern of keratoderma </li> <li>Increased risk of cutaneous SCC </li> <li>EB nevi may occur </li> </ul> </td> <td> <ul> <li>Oral mucosa </li> <li>Oesophageal blistering </li> <li>Recurrent blistering and fissuring around anal margin, exacerbating constipation </li> <li>Involvement of the conjunctiva and cornea </li> <li>Urethral strictures </li> </ul> </td> <td> <ul> <li>Nail dystrophy and loss secondary to trauma </li> </ul> </td> <td> <ul> <li>Nutritional impairment, growth retardation </li> <li>Anemia (iron deficiency, inflammation) </li> <li>Constipation (anal fissuring and blistering, exacerbated by poor intake of fiber-rich foods) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>Severe RDEB</strong><br/> (previously RDEB generalized severe, Hallopeau-Siemens RDEB)</p> <p>AR</p> <p><em>COL7A1</em><br/> (biallelic nonsense, splice-site, deletion, insertion, small insertion/deletion, or missense mutations with homozygosity or compound heterozygosity, usually resulting in null alleles; revertant mosaicism [somatic mutation, intragenic crossover] and forward nonrevertant mosaicism with germline frameshift mutation and somatic splice-site mutation reported)</p> <p>Type VII collagen</p> </td> <td> <ul> <li>Widespread skin blistering from birth; from infancy, blistering is more marked <strong>over bony prominences</strong> </li> <li>Extensive <strong>scarring</strong> and flexion contractures of large joints and mitten deformities of hands and feet due to progressive pseudosyndactyly (digital fusion), flexion contractures, and distal resorption of digits; milia formation </li> <li>Congenital skin ulceration (uni- or bilateral, especially dorsomedial foot, ankle, medial lower leg) </li> <li>High risk for aggressive cutaneous SCC commonly arising in areas of repeated trauma, chronic wounds, and scarring from teen years onwards </li> <li>EB nevi may occur </li> </ul> </td> <td> <ul> <li>Oral mucosa: microstomia, ankyloglossia; dental overcrowding, malalignment; secondary caries due to progressive scarring </li> <li>Oesophageal blistering, strictures limiting oral nutritional intake </li> <li>Protein-losing enteropathy </li> <li>Recurrent blistering and fissuring around anal margin, exacerbating constipation </li> <li>Involvement of conjunctiva and cornea </li> <li>Urethral strictures </li> </ul> </td> <td> <ul> <li>Nail dystrophy and loss secondary to trauma during the first several years of life </li> <li>Scarring alopecia and crusting are common with increasing age </li> </ul> </td> <td> <ul> <li>Nutritional impairment common, impaired growth, delayed puberty </li> <li>Constipation (anal fissuring and blistering, exacerbated by poor intake of fiber-rich foods) </li> <li>Anemia (iron deficiency, inflammation) </li> <li>Osteopenia, osteoporosis vertebral fractures (reduced mobility, chronic inflammation, vitamin D and calcium deficiency, pubertal delay) </li> <li>Renal impairment and failure (acute kidney injury, poststreptococcal glomerulonephritis, renal amyloid, or IgA nephropathy) </li> <li>Cardiomyopathy (micronutrient deficiency, iron overload, drugs, viral causes) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>DDEB, pruriginosa</strong> and <strong>RDEB, pruriginosa</strong></p> <p>AD or AR</p> <p><em>COL7A1</em></p> <p>(monoallelic or biallelic mutations; no specific genotype-phenotype correlation)</p> <p>Type VII collagen</p> </td> <td> <ul> <li>Presents initially as localized or intermediate DDEB or RDEB in childhood and early adulthood; characterized by <strong>intensely pruritic</strong>, excoriated, violaceous papules or linear plaques and scars, particularly on lower legs, thighs, arms; may become progressive with spreading more proximally and onto arms from adolescence through adulthood; may coexist with nonpruriginosa DEB within families </li> <li>Milia common </li> </ul> </td> <td> <ul> <li>Variable </li> </ul> </td> <td> <ul> <li>Nail dystrophy </li> </ul> </td> <td>Â </td> </tr> <tr class="divider_bottom"> <td> <p><strong>DDEB, self-improving</strong> and <strong>RDEB, self-improving</strong><br/> (also known as bullous dermolysis of the newborn)</p> <p>AD or AR</p> <p><em>COL7A1</em><br/> (missense, in-frame deletion, premature termination codon, and alternative splicing mutations; self-improving associated with in-frame skipping of exons or with specific glycine substitutions)</p> <p>Type VII collagen</p> <p>Characteristic intraepidermal retention of type VII collagen on immunohistochemistry and stellate bodies in dilated, rough endoplasmic reticulum on transmission electron microscopy</p> </td> <td> <ul> <li>Skin blistering presents at or shortly after birth, usually on extremities, with scarring and milia formation; skin fragility improves spontaneously and may resolve completely over first year or two of life </li> <li>Aplasia cutis of the lower limbs may be present </li> </ul> </td> <td> <ul> <li>Variable </li> </ul> </td> <td> <ul> <li>Nail dystrophy may persist throughout life </li> </ul> </td> <td>Â </td> </tr> <tr class="divider_bottom"> <td> <p><strong>RDEB inversa</strong></p> <p>AR</p> <p><em>COL7A1</em><br/> (compound heterozygosity for loss-of-function and missense mutation; specific glycine and arginine substitution mutations may affect thermostability of type VII collagen)</p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized skin blistering of intermediate severity in neonatal period and childhood; predilection for flexural sites (axillae, groins, perianal area, natal cleft) develops from adolescence to early adulthood </li> <li>Marked vulvovaginal and inframammary skin blistering in women </li> </ul> </td> <td> <ul> <li>Mouth and oesophagus </li> </ul> </td> <td> <ul> <li>Nail involvement </li> </ul> </td> <td> <ul> <li>External auditory canal with narrowing or complete occlusion </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>RDEB, localized</strong></p> <p>AR</p> <p>Compound heterozygosity for <em>COL7A1</em> missense, splice-site, and frameshift mutations</p> <p>Type VII collagen</p> </td> <td> <ul> <li>Skin fragility at or shortly after birth, rarely late onset in adulthood </li> <li>Limited blistering, predominantly of hands and feet or pretibial area </li> </ul> </td> <td> <ul> <li>Oral and esophageal mucosal involvement mild or absent </li> </ul> </td> <td> <ul> <li>Nail dystrophy and loss </li> </ul> </td> <td>Â </td> </tr> <tr> <td> <p><strong>Dominant and recessive compound heterozygous DEB</strong></p> <p>AD and AR</p> <p><em>COL7A1</em><br/> (compound heterozygosity for a dominant glycine substitution mutation and a recessive mutation on second allele)</p> <p>Type VII collagen</p> </td> <td> <ul> <li>Severe skin fragility presenting from birth, indistinguishable from severe RDEB </li> </ul> </td> <td> <ul> <li>Severe mucosal fragility presenting from birth, indistinguishable from severe RDEB </li> </ul> </td> <td> <ul> <li>Nail involvement </li> </ul> </td> <td>Â </td> </tr> </tbody></table></div><div class="graphic_footnotes">DDEB: dominant dystrophic epidermolysis bullosa; AD: autosomal dominant; SCC: squamous cell carcinoma; EB: epidermolysis bullosa; RDBE: recessive dystrophic epidermolysis bullosa; AR: autosomal recessive; IgA: immunoglobulin A; DEB: dystrophic epidermolysis bullosa.</div><div class="graphic_reference">References:

<ol>
<li>Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol 2020.</li>
<li>Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 2014; 70:1103.</li>
</ol></div><div id="graphicVersion">Graphic 129161 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
